Teladoc Health to Announce Second-Quarter 2019 Financial Results
Get Alerts TDOC Hot Sheet
Join SI Premium – FREE
PURCHASE, NY, July 12, 2019 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that it will release second-quarter 2019 results on Wednesday, July 31st, 2019, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
Conference Call DetailsThe conference call can be accessed by dialing 1-833-241-4255 for U.S. participants, or 1-647-689-4206 for international participants, referencing “Teladoc Health Call”; or via a live audio webcast that will be available online at http://ir.teladochealth.com/news-and-events/events-and-presentations/.
A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Teladoc HealthA mission-driven organization, Teladoc Health, Inc. is successfully transforming how people access and experience healthcare, with a focus on high quality, lower costs, and improved outcomes around the world. The company’s award-winning, integrated clinical solutions are inclusive of telehealth, expert medical services, AI and analytics, and licensable platform services. With more than 2,000 employees, the organization delivers care in 130 countries and in more than 30 languages, partnering with employers, hospitals and health systems, and insurers to transform care delivery. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.
Investor Contact: Bob East, Asher Dewhurst, Jordan KohnstamWestwicke 443-213-0500 [email protected]
Media Contacts: Courtney McLeod Teladoc Health 914-265-6789 [email protected]
Source: Teladoc Health, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amkor Tech jumps 9% as BofA initiates Buy with $70 target on AI surge
- MBX Biosciences doses first patient in Phase 3 hypoparathyroidism trial
- Abercrombie & Fitch (ANF) PT Raised to $185 at UBS on Growth Potential
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Twitter, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share